Astrazeneca to invest $285m in biologics facility in Sweden
Published 18/05/2015 | 09:28
Astrazeneca is to invest $285m at a biologics manufacturing facility in Södertälje, Sweden.
The investment is the first phase of a potential three-part programme to expand Astrazeneca's biologics manufacturing capabilities
Subject to relevant approvals by local authorities, the plant will create between 150 and 250 highly skilled new roles at Astrazeneca by 2019.